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Emergence of Myasthenia Gravis with Myositis  
in a Patient Treated with Pembrolizumab 
for Thymic Cancer
Dear Editor, 
A 34-year-old woman presented with a 4-week history of diplopia, dysphagia, and dyspnea. 
She had no previous history of a neuromuscular disorder. However, she had been diag-
nosed with thymic cancer (squamous cell carcinoma) 2 years previously, with metastasis to 
the pericardium, pleura, and lung, which had not been successfully treated with convention-
al chemotherapy (cyclophosphamide, vincristine, doxorubicin, and cisplatin). She had been 
treated with four cycles of 100-mg pembrolizumab every 2 weeks, which reduced the size of 
the tumor. 
A physical examination revealed bilateral ptosis, ophthalmoplegia, dysarthria, facial diple-
gia, hypophonia, and weakness of the palatal and neck flexor muscles. Her deep tendon re-
flexes were symmetrically decreased. Laboratory studies showed a markedly elevated serum 
creatine kinase (CK) level of 2,125 U/L and seropositivity for acetylcholine-receptor anti-
bodies (0.86 nmol/L). The findings of nerve conduction studies, repetitive nerve stimulation, 
and brain MRI were normal. Electromyography findings were suggestive of active myopathy. 
Based on the clinical and laboratory findings, we made a clinical diagnosis of myasthenia 
gravis (MG) with myositis associated with pembrolizumab. Pembrolizumab was discontin-
ued and the patient underwent a 5-day course of intravenous immunoglobulin (IVIg). She 
was then subsequently treated with a 3-day course of 1-g intravenous methylprednisolone 
(IVMP), followed by prednisolone (1 mg/kg). The CK level normalized (230 U/L) and her 
neck weakness improved after IVMP treatment. However, five cycles of plasmapheresis were 
applied due to aggravation of dyspnea. The dysphagia and ptosis had improved at the 6-month 
follow-up, but ophthalmoplegia and mild dyspnea persisted even though she was on continu-
ous prednisolone treatment. Additionally, the thymic cancer remained the same even without 
additional chemotherapy. 
Pembrolizumab is a monoclonal antibody targeting the programmed cell death 1 (PD-1) 
that is clinically beneficial in the treatment of malignancies such as metastatic melanoma and 
other advanced solid tumors, for which conventional therapies are only weakly effective.1 
Pembrolizumab binds to PD-1, which is an inhibitory signaling receptor expressed on the sur-
face of activated T cells, resulting in pembrolizumab preventing the binding of PD-1 to other 
ligands, thereby increasing the effectiveness of the T-cell-mediated immune response against 
tumor cells. However, enhanced immune activation by a PD-1 inhibitor may induce adverse 
side effects. It is particularly notable that autoimmune events in the neuromuscular system 
have also been reported in patients with metastatic melanoma who were treated with pem-
brolizumab (Table 1).2-9
Unlike the previously published cases in which metastatic melanoma was the underlying 
cancer, our patient had a thymic carcinoma. It is well known that thymic abnormalities and 
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thymic cancer can be associated with MG. It is therefore not 
clear in the present case whether MG with myositis was trig-
gered by pembrolizumab or whether MG was a manifestation 
of the underlying thymic carcinoma. However, our case is simi-
lar to previous cases in terms of its clinical presentation and the 
temporal relationship between the administration of pembroli-
zumab and the development of clinical symptoms. Therefore, 
the present treatment with pembrolizumab may have induced 
MG or aggravated latent MG. The clinical outcomes of auto-
immune complications induced by pembrolizumab vary from 
complete improvement to death.2-9 After discontinuing the PD-1 
inhibitor, early treatment comprising steroid pulse, plasma-
pheresis, or IVIg is important in suspected cases of neuromus-
cular impairment. Clinicians should be updated about the 
possibility that newly developed anticancer drugs can induce 
neuromuscular impairment. 
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Table 1. Case reports of neuromuscular disorder after pembrolizumab administration 
Age/sex 
reference
Underlying  
disease
Symptom 
onset* (weeks)
Symptoms Diagnosis CK (U/L) AChR ab* Immuno-therapy Outcome
34/F 
(our case)
Thymic cancer 8 EOM limitation, ptosis, 
neck weakness, 
dyspnea, dysphagia, 
and hypophonia 
MG with 
myositis
2,125 + IVIg, IVMP, 
PLEX, prednisone
Partial recovery
86/F2 Metastatic 
melanoma
6 EOM limitation, 
ptosis, proximal limb 
weakness, fatigue, 
and dysphonia
Necrotic 
myositis
1,499 - IVMP, PLEX Recovery
69/F3 Metastatic 
melanoma
9 EOM limitation, ptosis, 
dyspnea, and general 
weakness
MG ↑ - IMVP, PLEX No significant 
recovery, died 
due to brain 
metastasis
75/M4 Metastatic 
melanoma, 
well-controlled 
MG
5 Ptosis, dyspnea, and 
neck and proximal 
limb weakness
Exacerbation of 
MG
NR + IVIg, prednisone Recovery
59/F5 Metastatic 
melanoma, 
well-controlled 
MG
12 Dyspnea, dysphagia 
with dysarthria, and 
general weakness
Exacerbation of 
MG
NR - PLEX, IVIg, 
prednisone
Recovery
71/F6 Metastatic 
melanoma
12 EOM limitation, 
dysphagia, dysarthria, 
and neck and proximal 
limb weakness
MG 1,200 - Prednisone Recovery, 
died due to 
underlying 
cancer
78/M7 Metastatic 
melanoma
8 Ptosis, facial weakness, 
dyspnea, dysphagia, 
dysarthria, proximal 
limb weakness, and 
myalgia
Necrotic 
myopathy over 
a NMJ disorder
1,284 - PLEX, prednisone No significant 
recovery, 
passed away
63/M8 Metastatic 
melanoma
2 EOM limitation, ptosis, 
facial weakness, 
dyspnea, and 
periorbital edema with 
erythema
MG with 
myositis
10,386 + IVIg, IVMP, PLEX, 
prednisone
No significant 
recovery, died
85/F9 Metastatic 
melanoma
4.5 Diplopia and ptosis Ocular MG NR - IVIg, prednisone Recovery
*After administering pembrolizumab.
AChR ab: acetylcholine-receptor antibody, CK: serum creatine kinase, EOM: extraocular muscle movement, F: female, IVIg: intravenous immunoglobu-
lin, IVMP: intravenous methylprednisolone, M: male, MG: myasthenia gravis, NMJ: neuromuscular junction, NR: not reported, PLEX: plasmapheresis.
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